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Abstract
Background: Type 2 Diabetes Mellitus is one of the most disabling chronic conditions worldwide, resulting in 
significant human, social and economic costs and placing huge demands on health care systems. The Inala Chronic 
Disease Management Service aims to improve the efficiency and effectiveness of care for patients with type 2 diabetes 
who have been referred by their general practitioner to a specialist diabetes outpatient clinic. Care is provided by a 
multidisciplinary, integrated team consisting of an endocrinologist, diabetes nurse educators, General Practitioner 
Clinical Fellows (general practitioners who have undertaken focussed post-graduate training in complex diabetes 
care), and allied health personnel (a dietitian, podiatrist and psychologist).
Methods/Design: Using a geographical control, this evaluation study tests the impact of this model of diabetes care 
provided by the service on patient outcomes compared to usual care provided at the specialist diabetes outpatient 
clinic. Data collection at baseline, 6 and 12-months will compare the primary outcome (glycaemic control) and 
secondary outcomes (serum lipid profile, blood pressure, physical activity, smoking status, quality of life, diabetes self-
efficacy and cost-effectiveness).
Discussion: This model of diabetes care combines the patient focus and holistic care valued by the primary care sector 
with the specialised knowledge and skills of hospital diabetes care. Our study will provide empirical evidence about the 
clinical effectiveness of this model of care.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12608000010392.
Background
Type 2 Diabetes Mellitus (T2DM) is one of the most dis-
abling chronic conditions worldwide, resulting in signifi-
cant human, social and economic costs and placing huge
demands on health care systems[1]. It affects more than
880,000 Australians 25 years or older[2], and the preva-
lence is increasing as more people develop the condition,
the detection of the condition improves, and people with
the condition live longer[3]. People with T2DM are at risk
of acute and chronic micro- and macro-vascular compli-
cations including retinopathy, nephropathy, neuropathy,
peripheral vascular disease, coronary heart disease and
stroke; as well as mental health problems associated with
living with a chronic disease. The United Kingdom Pro-
spective Diabetes Study has demonstrated that rigorous
glycaemic control can significantly reduce diabetic com-
plications[4], underscoring the need for, and benefits of,
early diagnosis and appropriate management.
I n  A u s t r a l i a ,  m o s t  p e o p l e  w i t h  T 2 D M  r e c e i v e  t h e
majority of their diabetes care from their general practi-
tioner (GP)[5]. In 2006/07, it was the second most fre-
quently managed chronic problem in Australian general
practice, and was the reason for 3.7% of general practice
encounters; a 42% increase from 1998/99[6]. Around 5%
of consultations for diabetes lead to a referral by the GP
for specialist level care, most commonly to specialist dia-
betes outpatient clinics[6]. However, due to the increas-
ing prevalence of the condition and the finite capacity of
specialist outpatient clinics, new models of meeting com-
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munity needs for complex diabetes management are
required.
The Chronic Care Model (CCM) is a well known model
of care for people with chronic conditions that suggests
that optimal health outcomes are achieved when a pre-
pared and proactive practice team interacts with
informed and activated patients[7]. This model has
informed policy and been adapted for use in different
countries and different health care systems for caring for
patients with various chronic conditions, including
T2DM[8]. The model describes the six elements consid-
ered to be essential for improving the care of people with
chronic disease. These elements include delivery system
design, self management support, decision support, clini-
cal information systems, community resources and
health care organisations.
The Inala Chronic Disease Management Service
(ICDMS) is a new model of T2DM care that is informed
by the CCM with a particular focus on redesigning the
health care delivery system and improving patients' self
management skills - two of the six key elements of the
CCM. The conceptualisation of the ICDMS was
informed by the knowledge that there were unacceptably
long waiting lists for patients to gain access to specialist
diabetes outpatient clinics; the belief that with adequate
training and support, primary care providers could pro-
vide high quality care for people with diabetes; and the
desire to increase efficiency of care by making better use
of the skills of providers. The aim of the intervention was
to improve the efficiency and effectiveness of care with
the flow on effects of potentially being more cost effec-
tive. This paper describes the ICDMS clinical model and
the methods used to evaluate it, and provides baseline
data from the participants. The discussion highlights the
challenges faced, and the trade-offs between service
delivery and experimental control in the context of this
effectiveness trial.
The ICDMS clinical model
The ICDMS operates from within a general practice that
is co-located within the Inala Community Health Centre.
Care is provided by a multidisciplinary team consisting of
an endocrinologist, GP Clinical Fellows (GPs who have
undertaken focussed post-graduate training in complex
diabetes care), diabetes nurse educators, dietitian, podia-
trist and psychologist. The ICDMS clinical model has
three discrete components: the assessment and complica-
tions screening; the weekly multidisciplinary diabetes
clinic; and the review and discharge phase. The ICDMS
clinical model aims to enable each patient achieve target
levels for blood glucose, lipids, and blood pressure (BP),
or as close to target as realistic, and to then return to their
referring GP as soon as practicable for their ongoing dia-
betes care. The key elements of the clinical model are pre-
sented in Figure 1.
Comprehensive assessment and complications screening
At the patient's first visit to the ICDMS, a diabetes nurse
educator completes a comprehensive assessment and
complications screening. This assessment includes
anthropometric data, self-reported current medications
(prescription, over-the-counter medications, and com-
plementary medicines), relevant diabetes history (year of
diagnosis, family history of diabetes, previous gestational
diabetes, frequency of hypoglycaemic episodes, day-to-
day glycaemic control, and frequency of self monitoring
of blood glucose levels), smoking status, alcohol con-
sumption, current physical activity levels, weight man-
agement, and relevant medical history including known
macro- and microvascular complications of diabetes.
Retinopathy screening is conducted on site using a non-
mydriatric camera with retinal photographs taken by a
trained nurse and interpreted by a trained GP[9]. The
patient's feet are screened, and any patients with acute
foot complications or with a "high risk" foot are immedi-
ately referred to the ICDMS podiatrist for assessment.
Results from existing pathology tests for glycated haemo-
globin (HbA1c), serum lipids, folate, vitamin B12, creati-
nine, liver function tests, and urinary albumin:creatinine
ratio are used if tested within the previous three months.
If not, patients are provided with pathology request slips.
An onsite, publicly funded, pathology collection point
facilitates the timely processing of requests.
Weekly multidisciplinary clinic
The ICDMS multidisciplinary clinic is conducted one
morning per week and is serviced by all members of the
team (endocrinologist, GP Clinical Fellows, diabetes
nurse educators, dietitian, podiatrist, and psychologist).
In consultation with the patient, the GP Clinical Fellow
reviews the information gathered during the patient's
assessment and complications screening, determines the
patient's own goals for diabetes treatment, and develops a
patient specific management plan to address the identi-
fied issues. The endocrinologist reviews the management
plans and co-consults with the GP Clinical Fellow if the
patient's clinical issues are particularly complex. Evi-
dence-based guidelines or protocols inform management
of hyperglycaemia[10,11], chronic kidney disease[12],
hypertension[13], dyslipidemia[13,14], and macrovascu-
lar disease[13]. Referrals to an ophthalmologist are made
if retinopathy or other sight threatening pathology is
detected, as per Australian National Health and Medical
Research Council (NHMRC) guidelines[15]. Referrals are
also made to the allied health personnel for immediate
assessment and follow-up as required.Askew et al. BMC Health Services Research 2010, 10:134
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To ensure timely and comprehensive communication
between the ICDMS and the referring GP, a summary of
the assessment and management plan is forwarded to the
GP within one week of the patient attending the clinic.
This summary also includes any specific recommenda-
tions for the GP to follow-up, and informs the GP if the
patient has been discharged from the ICDMS. GPs are
provided with a direct contact number at the ICDMS for
queries, concerns and rapid re-assessment of patients.
Review and discharge
Phase Three focuses on execution of the management
plan developed at the clinic, with the aim of discharging
the patient back to their referring GP as soon as targets
have been reached and stabilised. Patients newly com-
menced on insulin, or those who need their insulin regi-
mens revised to achieve optimal glycaemic control are
enrolled into the ICDMS insulin stabilisation service
(ISS). Patients on the ISS are contacted two or three times
a week by a diabetes nurse educator to review their daily
blood sugar levels (BSLs). Under supervision of a GP
Clinical Fellow, the diabetes nurse educator makes small,
incremental adjustments to the patient's insulin regimen
to achieve stable and optimal BSLs. Patients are reviewed
at the weekly clinic as required to monitor and adjust
other treatments. Where appropriate, patients are
strongly encouraged to attend either the self-manage-
ment or weight loss programs provided by the ICDMS or
other relevant programs provided by the Inala Commu-
nity Health Centre.
Methods/Design
Study aim and design
The overarching aim of the ICDMS clinical model is to
provide comprehensive and integrated clinical care for
people with complex T2DM to achieve optimal glycaemic
control. An open controlled intervention trial is compar-
ing the impact of the ICDMS clinical model on patient
outcomes compared to usual care provided to compara-
ble patients attending the Princess Alexandra Hospital
(PAH) Specialist Diabetes Outpatient Clinic. Figure 2
shows the study design. Usual care at the PAH involves
assessment and review by a consultant endocrinologist or
supervised training registrars or residents and referral to
a diabetes nurse educator or other allied health personnel
as required. Patients that have relatively stable control
tend to not be discharged back to their referring GP, but
continue to attend the clinic for annual reviews.
Patient population and recruitment
The target population for the ICDMS evaluation study
was patients with T2DM who had been referred by their
Figure 1 Flowchart describing study design for evaluating Inala Chronic Disease Management Service clinical model.
Patients from GP practices willing 
to be treated at the ICDMS 
Evaluation 
Clinical indicators, Quality of Life, 
Diabetes Self Efficacy & Depression 
Patients of GPs in Inala catchment area 
referred to PAH endocrinology outpatients 
clinic  
Patients from GP practices 
preferring for patients to receive 
care at PAH 
Patients managed at PAH 
endocrinology outpatients clinic 
Patients from outside ICDMS 
catchment referred to PAH 
endocrinology outpatients clinic 
Patients managed at ICDMS & shared 
care arrangement between GP & ICDMS 
Evaluation  
Clinical indicators, Quality of Life, 
Diabetes Self Efficacy 
Control Group  Intervention Group Askew et al. BMC Health Services Research 2010, 10:134
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GP to the PAH specialist diabetes outpatient clinic. Both
new and existing patients of the specialist diabetes outpa-
tient clinic who were at least 18 years old and able and
willing to provide informed consent were eligible to par-
ticipate. Interpreter services were available for patients
who needed assistance with their English. Exclusion cri-
teria included being on haemodialysis, renal transplant
patients because of their need for frequent visits to the
tertiary hospital, hypoglycaemic unawareness, or preg-
nancy.
Recruitment of patients to the ICDMS occurred
between September 2007 and April 2008. The ICDMS
focussed on patients who lived within the Queensland
Health designated catchment area for the Inala Commu-
nity Health Centre or attended a GP who practiced
within this area who had been referred by their GP to the
PAH specialist outpatient clinic. These patients were
identified from the PAH specialist outpatient clinic's
appointment booking system. Approval was sought from
the patient's GP for the ICDMS to contact the patient by
letter and/or phone to invite them to attend the ICDMS
rather than the PAH specialist outpatient diabetes clinic.
No GP refused consent for their patient to attend the
ICDMS, and all patients invited to attend the ICDMS did
so. All patients attending the ICDMS underwent the ini-
tial comprehensive assessment and complications screen-
ing described above, irrespective of previous attendances
at the PAH.
One hundred and forty nine consecutive patients with
T2DM attending the PAH specialist diabetes outpatients
clinic from January to April 2008 were invited to partici-
pate in this study as the control group. Their recruitment
occurred in the clinic whilst they waited for their
appointment with the specialist. Only four patients
refused to participate.
Sample size and power calculation
A total of 240 patients (120 per group) were needed to
detect a difference between study groups of 0.5% in the
change in HbA1c from baseline, assuming a standard
deviation of HbA1c (our primary outcome) of 1.4%, using





Eligible patients from the ICDMS catchment, referred to Princess Alexandra 
Hospital Specialist Diabetes Outpatients have their diabetes care managed by at 
ICDMS  
Diabetes nurse educator completes comprehensive assessment and 
complications screening 
Weekly multidisciplinary clinic: GP Clinical Fellow develops management.  
Specialist available to review management and for co-consultation with GP 
Clinical Fellow if required. Dietitian, podiatrist and psychologist available for 
consultation if required. 
Institution of management plan at ICDMS following evidence based protocols.  
GP Clinical Fellow supervises insulin stabilisation service.  Patients discharged 
back to GP when best possible blood pressure, lipid and glucose targets 
achieved.   Askew et al. BMC Health Services Research 2010, 10:134
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a 2-sided test with a significance level of 0.05 and 80%
power. We estimated a 20% discontinuation rate for the
12 month follow-up period, thus we aimed to enrol 300
patients (150 per group).
Outcome assessment
Data from patients were collected at baseline by review-
ing medical records for clinical data and self-completed
questionnaires for demographic data, including age, edu-
cation level, ethnicity, duration of diabetes, and history of
co-morbidities. Clinical data will be collected again at six
and 12 months in similar fashions.
The ICDMS aimed to enable patients to achieve opti-
mal glycaemic control and therefore, the primary out-
come is HbA1c at 12 months. The proportion of patients
with HbA1c ≤ 7% (ie. within the NHMRC guidelines for
glycaemic control[15]; between 7.1% and ≤ 8%; between
8.1% and 10%; and greater than 10% will be calculated
and compared between groups.
Secondary outcome measures include improvements in
modifiable cardiovascular disease risk factors, and
improvements in patient quality of life and diabetes self-
efficacy. Improvements in modifiable cardiovascular dis-
ease risk factors include decreased total and low density
lipoprotein (LDL) cholesterol and blood pressure (BP),
increased levels of physical activity, and increased pro-
portion of non-smoking participants. Additionally, the
proportion of participants with BP and LDL cholesterol
at target will be assessed at 12 months. Quality of care
indicators included the proportion of patients with
microalbuminuria on Angiotensin-Converting Enzyme
(ACE) inhibitors or Angiotensin 2 Receptor Antagonists
(A2RB); the proportion of patients with dyslipideamia on
statins or fibrates (if indicated and tolerated); and the
proportion of patients on prophylactic aspirin (as was
accepted best practice at the commencement of this
study).
Changes in health status will be assessed using the
EuroQoL 5-Dimension (EQ-5D) scale. This standardised,
five item descriptive system and visual analog scale mea-
sures mobility, self-care, pain, usual activities and anxiety
and contributes to a 'utility' score[16] and was chosen to
enable an international comparison of the cost-effective-
ness of the project. Changes in diabetes self efficacy, or an
"individual's judgement of confidence to carry out tasks
specific to diabetes management" will be assessed using
the 18-item Diabetes Self Efficacy Scale. This scale
assesses an individual's sense of certainty or uncertainty
about their ability to manage their condition, and their
perceived ability to follow diabetic routines, self-treat,
exercise and follow an appropriate dietary plan[17].
Changes in the prevalence and severity of depression will
be assessed in the intervention group using the depres-
sion module of Patient Health Questionnaire (PHQ-
9)[18] but not in the control group as it was beyond the
scope of this project to provide clinical care for any con-
trol patients identified with significant levels of depres-
sion via this assessment.
Statistical analysis
Baseline characteristics that differ significantly between
the two patient groups and the two groups of general
practices will be identified using descriptive statistics and
adjusted for in all multivariate analyses. Characteristics of
pa rt i ci pa n ts  w h o  c o m p l e t e  a n d  wi t h d r a w  wi l l  be  c o m -
pared. To ensure the generalisability of the results, the
number of non-participants, their age and gender, and
their reason for non-participation will be recorded.
Analyses of primary outcomes will be done on an inten-
tion to treat basis assuming return to baseline values for
any patients who do not complete follow-up. Measures of
the outcome value at baseline will be included in the
regression analysis as a covariable. Other covariables may
include any characteristics that are not balanced between
the groups at baseline. A sensitivity analysis will investi-
gate the effect of participant loss to follow-up on the
intervention effect. Statistical significance will be based
on two-tailed tests, with p < 0.05 considered significant.
Baseline results
A total of 335 patients participated in this study: 185 in
the ICDMS group and 145 in the control group. Only
four patients in the control group declined to participate
in the study.
Baseline clinical characteristics and demographic data
for control and intervention patients are presented in
Table 1. There were no significant differences between
groups for known duration of diabetes, self-reported dia-
betes treatment, country of origin, smoking status, level
of physical activity, Body Mass Index (BMI), weight and
serum cholesterol. ICDMS patients were significantly
younger, were less likely to be male, had significantly
lower levels of education, higher levels of HbA1c, lower
blood pressure, and were less likely to have neuropathy.
Trial organisation and management
The ICDMS received ethical approval from the PAH
Human Research Ethics Committee: 2007/100. No signif-
icant risks to patients or GPs were anticipated, and as the
study was unblinded and low risk a data monitoring com-
mittee was not necessary. The trial is registered with the
Australian New Zealand Clinical Trials Registry,
ACTRN12608000010392. http://www.anzctr.org.au/
default.aspx
A steering group comprising of representatives of
Queensland Health, The University of Queensland, and
the local Division of General Practice provided strategic
oversight to the project. In addition, operational and eval-Askew et al. BMC Health Services Research 2010, 10:134
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Table 1: Demographic and clinical characteristics of participants in usual care (n = 145) and ICDMS (n = 185) groups.
Usual Care ICDMS P
Age in years, mean (standard deviation (SD)) 62.9 (11.6) 59.4 (13.4) 0.01
Duration of diagnosed diabetes in years, mean (SD) 13.7 (0.9) 12.8 (0.8) 0.47
Diabetes treatment 0.68
Non-pharmacological 5( 4 % )5( 3 % )
Oral hyperglycaemics 61 (46%) 68 (41%)
Oral hyperglycaemics and insulin 41 (31%) 62 (37%)
Insulin only 25 (19%) 32 (19%)
Sex (male) 93 (64%) 83 (45%) 0.001
Country of origin 0.30
Australia 87 (61%) 78 (51%)
UK and Ireland 13 (9%) 17 (11%)
New Zealand 9( 6 % )7( 5 % )
Europe 12 (8%) 12 (8%)
Asia 9( 6 % ) 1 3 ( 9 % )
Other 13 (9%) 26 (17%)
Aboriginal or Torres Strait Islander 3 (2%) 8 (4%) 0.36
Smoking 0.74
Never 55 (42%) 64 (39%)
Ex-smoker 59 (45%) 74 (45%)
Current smoker 17 (13%) 26 (16%)
Education level 0.51
No formal qualifications 36 (27%) 36 (23%)
School/Intermediate Certificate 25 (19%) 34 (21%)
Higher School Certificate 25 (19%) 40 (25%)
Diploma or Apprenticeship 35 (27%) 42 (26%)
University Degree 11 (8%) 8 (5%)Askew et al. BMC Health Services Research 2010, 10:134
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BMI (kg/m2), mean (SD) 31.8 (6.3) 33.3 (8.3) 0.08
Weight (kg), mean (SD) 91.5 (22.5) 91.0 (25.9) 0.85
HbA1c (%), mean (SD) 7.9 (1.9) 8.5 (1.9) 0.001
HbA1c ≤ 7% 54 (38%) 37 (22%) 0.003
Sitting systolic BP (mmHg), mean (SD) 140 (19) 130 (16) <0.001
Sitting diastolic BP (mmHg), mean (SD) 77 (11) 72 (11) <0.001
Blood Pressure ≤ 130/80 mmHg, mean 48 (33%) 99 (56%) <0.001
Total Cholesterol (mmol/L), mean (SD) 4.2 (1.1) 4.3 (1.1) 0.47
HDL-cholesterol (mmol/L), mean (SD) 1.1 (0.3) 1.1 (0.4) 0.69
LDL-cholesterol (mmol/L), mean (SD) 2.5 (2.4) 2.4 (0.8) 0.50
LDL-cholesterol ≤ 2.5 (mmol/L) 86 (67%) 96 (63%) 0.62
Triglycerides, mean (SD) 1.9 (1.5) 2.3 (4.1) 0.37
Neuropathy 73 (56%) 53 (31%) <0.001
Retinopathy 53 (41%) 36 (33%) 0.28
Ischaemic heart disease 38 (34%) 56 (39%) 0.51
Variables in usual care group with missing data: 1 observation missing for HbA1c; 3 observations missing for triglycerides; 5 observations missing 
for Aboriginality; 11 observations missing for duration of diabetes and HDL-cholesterol; 13 observations missing for diabetes treatment, country 
of origin, and highest education level; 14 observations missing for smoking and retinopathy; 15 observations missing for neuropathy; 16 
observations missing for LDL-cholesterol; and 33 observations missing for ischaemic heart disease.
Variables in ICDMS group with missing data: 5 observations missing for Aboriginality; 8 observations missing for weight and BMI; 9 observations 
missing for blood pressure; 12 observations missing for neuropathy; 14 observations missing for total cholesterol; 15 observations missing for 
triglycerides; 16 observations missing for HbA1c; 18 observations missing for diabetes treatment; 21 observations missing for country of origin 
and smoking status; 25 observations missing for highest education level; 29 observations missing for HDL-cholesterol; 33 observations missing 
for LDL-cholesterol; 40 observations missing for ischaemic heart disease; 41 observations missing for duration of diabetes; and 76 observations 
missing for retinopathy.
Table 1: Demographic and clinical characteristics of participants in usual care (n = 145) and ICDMS (n = 185) groups. 
uation committees provided input into the day-to-day
management of the project.
Discussion
The increasing prevalence of T2DM in the community is
placing significant demands on health care systems. The
pivotal role of primary care in providing care for people
with T2DM is increasingly being recognised, as is the
need to develop new models of care that deliver improved
quality, efficiency and patient engagement in care.
We believe the ICDMS is a unique model of diabetes
care. It is not a specialist outreach service where a spe-
cialist health service is provided to a community on a vis-
iting basis. It is a new model of care delivered by GPs who
have undertaken advanced skills training (the ICDMS GP
Clinical Fellows) with on-site specialist support from the
endocrinologist and a multidisciplinary team. The initial
comprehensive assessment ensures efficiency of the con-
sultation between the patient and the GP Clinical Fellow.
The support provided by the endocrinologist to GP Clini-
cal Fellows not only ensures the quality of care provided
to the patients, but also contributed to the continuing
development of the GP Clinical Fellows' knowledge and
skills of complex diabetes management.
There are some similarities to specialist primary care
diabetes clinics seen in the United Kingdom. Similar toAskew et al. BMC Health Services Research 2010, 10:134
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the UK model of GPs with Special Interests (GPwSI), care
is provided by GPs who have undertaken additional train-
ing in a specific clinical area. The UK GPwSIs take refer-
rals for the assessment or treatment of patients that may
otherwise be referred directly to a secondary care consul-
tant: in other words, the GPs practice within the tradi-
tional model of the separation of primary and secondary
care[19]. In comparison, the ICDMS clinical model fea-
tures the GP Clinical Fellow, the on-site endocrinologist,
the diabetes nurse educator, and the allied health person-
nel working together to provide enhanced care for
patients in a primary care setting.
The ICDMS is also not a general practice diabetes clinic
where a general practice will have a clinical session
devoted to the care of its patients with T2DM. Patients
attending the ICDMS have been referred by their GP for
specialist level care which is provided by the ICDMS mul-
tidisciplinary team. Once glycaemic control is achieved
and the acute complications have been addressed, the
p a t i e n t  i s  d i s c h a r g e d  b a c k  t o  t h e i r  r e f e r r i n g  G P .  T h e
ICDMS does not provide a general practice service, and
other health issues not related to diabetes are not
addressed during the consultations, and patients are
advised to discuss these issues with their own GP.
This study does have limitations. We have used a geo-
graphical control to assess the effectiveness of the
ICDMS clinical model, as this was the most feasible study
design in the health service environment in which the
ICDMS was established. The differences at baseline
between the intervention and control groups demon-
strate the difficulties associated with this design, and the
need to account for these differences in the statistical
analysis. This research was conducted contemporane-
ously with the delivery of the clinical service. The major-
ity of clinicians involved in the service were not
researchers and were principally focused on clinical care
rather than ensuring the integrity of the experimental
design. At times this was challenging for the clinicians as
they struggled with the relative rigidity of implementing a
research protocol compared with clinical service delivery
that can be adjusted as deemed appropriate by individual
clinicians. Replication of this model of care requires a
greater understanding of the impact of this model on the
providers of care: their roles, satisfaction, and self-effi-
cacy to provide treatment could be investigated through
focus groups in both settings. However, this study
focused on the impact of the model of care on clinical
outcomes, rather than providers. Further research is
needed to investigate the later important area.
We believe that the ICDMS clinical model has consid-
e r a b l e  p o t e n t i a l ,  a n d  c o u l d  b e  t r a n s f e r a b l e  t o  o t h e r
chronic conditions and other geographical areas. Its
strengths include the comprehensive assessment and
complications screening process, the GP Clinical Fellows
value-adding to the clinical efficiency of the specialist
thereby increasing patient throughput, and its location
within the patients' community. We also believe that the
ICDMS clinical model combines the best of two health
care domains - the patient focus and holistic care valued
by the primary care sector with the specialised knowl-
edge and skills of hospital diabetes care. Our study will
provide empirical evidence about the clinical effective-
ness and the economic benefits of this model of care.
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